Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
about
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid LeukemiaEnhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.Enhancement of Antiangiogenic Efficacy of Iron(II) Complex by Selenium Substitution.Discovery of nicoyamycin A, an inhibitor of uropathogenic Escherichia coli growth in low iron environments.Mesoporous γ-Iron Oxide Nanoparticles for Magnetically Triggered Release of Doxorubicin and Hyperthermia Treatment.Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).
P2860
Q28072058-537EDACB-B844-4CF5-B0A5-EABA7BD44740Q33728180-7D76142D-E64F-4682-BD9F-332B57DE38BBQ36770191-D3F68EDB-48EE-4F66-A52B-85EDCF3BD9FDQ37204002-C7854ABD-D938-4F56-B334-A068C3748075Q38469793-942E68AC-73A3-4B9D-A00F-AF9F8456A533Q38664735-6953E76D-A705-4ADF-9C6B-20E029259A58Q38829544-D9D3AB3B-DC51-43D2-9B3A-939575B85B1BQ46425542-964AFE20-1356-478F-A492-C87DB1C8C72AQ48822702-10F24744-D121-4957-8070-0134096F44E7Q50006927-1E3945A8-0B4A-4CF5-80E8-68FB7FC2D809Q51138937-19023425-E250-463D-B46A-DAD971F0025CQ54964566-72A1BF89-C803-4A2B-89EB-72ED209E9390
P2860
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
@en
type
label
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
@en
prefLabel
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
@en
P2093
P2860
P356
P1433
P1476
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
@en
P2093
Chris Orvig
Gene Jamieson
Jacqueline F Cawthray
Judith A Fox
Katja Dralle Mjos
P2860
P304
P356
10.1039/C4DT02934H
P407
P577
2015-02-01T00:00:00Z